Chronic Menstrual Disorder Highlights Gaps in Indian Health Policy and Women’s Welfare

The severe pre‑menstrual condition known as premenstrual dysphoric disorder (PMDD) remains largely invisible within the Indian medical establishment, despite affecting a substantial proportion of adult women and producing episodic incapacitation that rivals many recognized chronic ailments; this invisibility is compounded by an absence of standardized diagnostic criteria in public hospitals and a dearth of specialist training among general practitioners.

Women laboring in both formal and informal sectors experience abrupt, week‑long periods of profound depression, irritability, and, in extreme cases, suicidal ideation, only to resume professional duties as swiftly as the menstrual flow begins, thereby perpetuating a cycle that undermines productivity, erodes job security, and reinforces gendered disparities in workplace accommodations.

Official responses from the Ministry of Health and Family Welfare have been limited to generic statements regarding mental health awareness, while concrete policy measures, such as inclusion of PMDD in the National Mental Health Programme or allocation of dedicated funding for research, remain conspicuously absent, revealing a troubling disconnect between rhetorical commitment and actionable governance.

Academic institutions and research councils have likewise demonstrated inertia, allocating negligible grant resources to studies on hormonal mood disorders, a shortfall that not only hampers the development of evidence‑based treatment protocols but also obstructs the formulation of legally defensible standards of care for women seeking redress under the Rights of Persons with Disabilities Act.

If the State persists in classifying PMDD as a peripheral mental health concern rather than a distinct, disability‑conferring condition, how can courts justify denying reasonable accommodations to affected employees under existing labour statutes, and what legal precedent might emerge should women collectively seek judicial enforcement of the Constitution’s equality guarantee in the face of administratively sanctioned neglect?

Should the Ministry be compelled to produce a transparent, time‑bound action plan that integrates PMDD into primary health‑care training curricula, mandates insurance coverage for approved pharmacological interventions, and establishes an independent oversight committee to monitor compliance, thereby transforming nominal policy rhetoric into enforceable public‑health obligations?

Will legislative bodies entertain amendments to the Clinical Establishments (Registration and Regulation) Act that expressly require hospitals to document and report PMDD‑related morbidity, enabling data‑driven allocation of resources and furnishing victims with the evidentiary foundation necessary to pursue civil remedies for systemic discrimination?

Published: May 17, 2026

Published: May 17, 2026